Cilian AG is an innovative biotechnology enterprise, which uses the unique abilities of Ciliates, a new class of production organisms, for the industrial production of therapeutic proteins. The company is working on production of vaccines, monoclonal antibodies as well as on oral enzyme preparation for the substitution therapy of pancreatic insufficiency. By using a new class of production organism (Ciliates) Cilian AG can design the production process substantially safer, more efficient and more cost-effective as this is currently possible for comparable proteins with mammalian cells. Moreover it is expected, that monoclonal antibodies can be developed and produced significantly more effective. Cilian is offering this unique technology as CIBEX-System to Pharma- and Biotech companies.
